These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 27955956)

  • 1. Maturity-Onset Diabetes of the Young: A Genetic Form of Diabetes in Children.
    Welsh KM
    J Pediatr Nurs; 2017; 32():89-90. PubMed ID: 27955956
    [No Abstract]   [Full Text] [Related]  

  • 2. HNF4A mutation: switch from hyperinsulinaemic hypoglycaemia to maturity-onset diabetes of the young, and incretin response.
    Arya VB; Rahman S; Senniappan S; Flanagan SE; Ellard S; Hussain K
    Diabet Med; 2014 Mar; 31(3):e11-5. PubMed ID: 24299156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype.
    Vilsbøll T; Knop FK; Krarup T; Johansen A; Madsbad S; Larsen S; Hansen T; Pedersen O; Holst JJ
    J Clin Endocrinol Metab; 2003 Oct; 88(10):4897-903. PubMed ID: 14557471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Type 2 diabetes: hypoinsulinism, hyperinsulinism, or both?
    Glaser B
    PLoS Med; 2007 Apr; 4(4):e148. PubMed ID: 17407388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HNF1A mutation presenting with fetal macrosomia and hypoglycemia in childhood prior to onset of overt diabetes.
    Dusátková P; Průhová S; Sumník Z; Kolousková S; Obermannová B; Cinek O; Lebl J
    J Pediatr Endocrinol Metab; 2011; 24(5-6):377-9. PubMed ID: 21823540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistent hyperinsulinemic hypoglycemia and maturity-onset diabetes of the young due to heterozygous HNF4A mutations.
    Kapoor RR; Locke J; Colclough K; Wales J; Conn JJ; Hattersley AT; Ellard S; Hussain K
    Diabetes; 2008 Jun; 57(6):1659-63. PubMed ID: 18268044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel glucokinase gene mutation and its effect on glycemic/C-peptide fluctuations in a patient with maturity-onset diabetes of the young type 2.
    Loomba-Albrecht LA; Jame M; Bremer AA
    Diabetes Res Clin Pract; 2010 Mar; 87(3):e23-5. PubMed ID: 20015564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incretin effect and glucagon responses to oral and intravenous glucose in patients with maturity-onset diabetes of the young--type 2 and type 3.
    Østoft SH; Bagger JI; Hansen T; Pedersen O; Holst JJ; Knop FK; Vilsbøll T
    Diabetes; 2014 Aug; 63(8):2838-44. PubMed ID: 24677712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young.
    Fajans SS; Bell GI; Polonsky KS
    N Engl J Med; 2001 Sep; 345(13):971-80. PubMed ID: 11575290
    [No Abstract]   [Full Text] [Related]  

  • 10. Growth factor signalling in the regulation of α-cell fate.
    Kawamori D; Akiyama M; Hu J; Hambro B; Kulkarni RN
    Diabetes Obes Metab; 2011 Oct; 13 Suppl 1():21-30. PubMed ID: 21824253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Familial hyperglycemia due to mutations in glucokinase. Definition of a subtype of diabetes mellitus.
    Froguel P; Zouali H; Vionnet N; Velho G; Vaxillaire M; Sun F; Lesage S; Stoffel M; Takeda J; Passa P
    N Engl J Med; 1993 Mar; 328(10):697-702. PubMed ID: 8433729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Definition, epidemiology and classification of diabetes in children and adolescents.
    Craig ME; Hattersley A; Donaghue KC
    Pediatr Diabetes; 2009 Sep; 10 Suppl 12():3-12. PubMed ID: 19754613
    [No Abstract]   [Full Text] [Related]  

  • 13. Incretin hormones and maturity onset diabetes of the young--pathophysiological implications and anti-diabetic treatment potential.
    Østoft SH
    Dan Med J; 2015 Sep; 62(9):. PubMed ID: 26324089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phenotypical aspects of maturity-onset diabetes of the young (MODY diabetes) in comparison with Type 2 diabetes mellitus (T2DM) in children and adolescents: experience from a large multicentre database.
    Schober E; Rami B; Grabert M; Thon A; Kapellen T; Reinehr T; Holl RW;
    Diabet Med; 2009 May; 26(5):466-73. PubMed ID: 19646184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Commentary: Type 2 diabetes and birth weight--genetic and environmental effects.
    Lindsay RS
    Int J Epidemiol; 2008 Feb; 37(1):192-3. PubMed ID: 18245056
    [No Abstract]   [Full Text] [Related]  

  • 16. beta Cell autoimmunity in a child with M.O.D.Y. (Maturity Onset Diabetes in the Young).
    Ortega-Rodriguez E; Levy-Marchal C; Guillermine S; Polak M
    Diabetes Metab; 2001 Feb; 27(1):59-61. PubMed ID: 11240447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of dysregulated glucagon secretion in type 2 diabetes.
    D'Alessio D
    Diabetes Obes Metab; 2011 Oct; 13 Suppl 1():126-32. PubMed ID: 21824266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HNF-4alpha: from MODY to late-onset type 2 diabetes.
    Gupta RK; Kaestner KH
    Trends Mol Med; 2004 Nov; 10(11):521-4. PubMed ID: 15519277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An integrated view of beta-cell dysfunction in type-II diabetes.
    Poitout V; Robertson RP
    Annu Rev Med; 1996; 47():69-83. PubMed ID: 8712804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Non-insulin dependent diabetes mellitus during development in the population ].
    Buczkowska EO; Chobot PJ
    Wiad Lek; 2001; 54(3-4):192-201. PubMed ID: 11436686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.